Drugs & Therapy Perspectives

, Volume 21, Issue 3, pp 1–4 | Cite as

Mitoxantrone reduces relapse rate and slows disease progression in worsening multiple sclerosis

Drug and Profile Reports


  1. 1.
    Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 2004; 18(6): 379–96PubMedCrossRefGoogle Scholar
  2. 2.
    Weinstock-Guttman B, Bakshi R. Combination therapy for multiple sclerosis: the treatment strategy of the future? CNS Drugs 2004; 18(12): 777–92PubMedCrossRefGoogle Scholar
  3. 3.
    Hartung H-P, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360(9350): 2018–25PubMedCrossRefGoogle Scholar
  4. 4.
    Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria [see comments]. J Neurol Neurosurg Psychiatry 1997; 62(2): 112–8PubMedCrossRefGoogle Scholar
  5. 5.
    Crossley RJ. Clinical safety and tolerance of mitoxantrone. Semin Oncol 1984; 11(3 Suppl. 1): 54–8PubMedGoogle Scholar
  6. 6.
    Edan G, Brassat D, Clanet M, et al. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients [abstract no. S23.005]. Neurology 2002; 58 Suppl. 3: A168Google Scholar
  7. 7.
    Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002 Sep 24; 59: 909–13PubMedCrossRefGoogle Scholar
  8. 8.
    Avasarala JR, Cross AH, Clifford DB, et al. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 2003 Feb; 9(1): 59–62PubMedCrossRefGoogle Scholar
  9. 9.
    Serono. Novantrone®: mitoxantrone for injection concentrate (US) [online]. Available from URL:[Accessed 2004 Nov 26]
  10. 10.
    Schleyer E, Kamischke A, Kaufmann CC, et al. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. Leukemia 1994; 8(3): 435–40PubMedGoogle Scholar
  11. 11.
    Smyth JF, Macpherson JS, Warrington PS, et al. The clinical pharmacology of mitoxantrone. Cancer Chemother Pharmacol 1986; 17(2): 149–52PubMedCrossRefGoogle Scholar
  12. 12.
    Becker CC, Gidal BE, Fleming JO. Immunotherapy in multiple sclerosis, part 2. Am J Health Syst Pharm 1995; 52(19): 2105–20PubMedGoogle Scholar
  13. 13.
    Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [published erratum appears in Neurology 2002; 59 (3): 480]. Neurology 2002; 58(2): 169–78PubMedCrossRefGoogle Scholar
  14. 14.
    Mikol DD, Bernitsas E. Safety and tolerability of mitoxantrone plus dexrazoxane therapy in multiple sclerosis patients [abstract no. P06.084]. Neurology 2002; 58 Suppl. 3: A459–60Google Scholar

Copyright information

© Adis Data Information BV 2005

Personalised recommendations